Subsequent Events	9 Months Ended
Sep. 30, 2025
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events. On October 1, 2025, the Company announced that its Board of Directors has approved a new share repurchase program authorizing the Company to repurchase up to $200 million of its common stock between October 1, 2025 and December 31, 2026. Repurchases under the new share repurchase program may be made through a variety of methods, including open market or privately negotiated purchases. The timing and amount of shares repurchased will depend on the stock price, business and market conditions, corporate and regulatory requirements, alternative investment opportunities, acquisition opportunities and other factors. The Company is not obligated to repurchase any specific amount of shares of common stock, and the new share repurchase program may be suspended or terminated at any time. The Company plans to use existing cash on hand to fund its new share repurchase program. As of November 3, 2025, the Company has repurchased 405,092 shares of its outstanding common stock for an aggregate purchase price of approximately $8.4 million ($20.74 average price per share). On October 2, 2025, KYE issued a press release announcing that Health Canada issued a Notice of Compliance for KYE's New Drug Submission to commercialize AGAMREE® in Canada.

Subsequent Events

9 Months Ended

Sep. 30, 2025

17.

Subsequent Events.

On October 1, 2025, the Company announced that its Board of Directors has approved a new share repurchase program authorizing the Company to repurchase up to $200 million of its common stock between October 1, 2025 and December 31, 2026. Repurchases under the new share repurchase program may be made through a variety of methods, including open market or privately negotiated purchases. The timing and amount of shares repurchased will depend on the stock price, business and market conditions, corporate and regulatory requirements, alternative investment opportunities, acquisition opportunities and other factors. The Company is not obligated to repurchase any specific amount of shares of common stock, and the new share repurchase program may be suspended or terminated at any time. The Company plans to use existing cash on hand to fund its new share repurchase program. As of November 3, 2025, the Company has repurchased 405,092 shares of its outstanding common stock for an aggregate purchase price of approximately $8.4 million ($20.74 average price per share).

On October 2, 2025, KYE issued a press release announcing that Health Canada issued a Notice of Compliance for KYE's New Drug Submission to commercialize AGAMREE® in Canada.